In the early 50s, American surgeon Charles Hufnagel, MD began saving lives with a first-of-its-kind plastic aortic assist valve. Today, thanks to this pioneering work, transcatheter aortic valve implantation (TAVI) is firmly established as a safe and effective procedure for treating symptomatic patients with severe aortic stenosis. And, the transcatheter mitral valve repair (TMVR) space is advancing quickly.
It’s been a rocky road of late in the bioresorbable scaffold space, following Abbott Vascular’s withdrawal of its once-heralded Absorb device from the market, and Boston Scientific halting development of its Renuvia scaffold. Despite these landscape-altering setbacks, smaller players, including REVA Medical, are standing strong and moving forward with the development and clinical testing of their proprietary scaffolds, believing that there is a promising future for this evolving technology. For Reggie Groves, CEO of REVA, her drive to succeed in one of today’s most challenging and highly scrutinized medtech markets comes down to the patients they serve.